| Author, YearTrial NameN | Drug, Dose X Duration (N) | Active TB Disease,N (%) | Transmission, N (%) | Quality of Life | Overall Mortality,N (%) | Disease-Specific Mortality,N (%) |
| --- | --- | --- | --- | --- | --- | --- |
| Bush, 196543All subjects:2,238 ≥15 years: 1,309≥20 years: 1,140 | INH 250 mg/day x 12 months (569).Placebo (571). | All subjects (adults and children):8 (0.73)a11 (0.96)bSubjects ≥15 years:4 (0.60)7 (1.08) | NR | NR | NRNR | NRNR |
| Falk, 197841,1487,036 | INH 300 mg daily x 2 years (2166).INH 300 mg daily x 1 year, followed by placebo x 1 year (2,553).Placebo daily x 2 years (2,317). | 17 (0.8) 20 (0.8) 26 (1.1) Among those with no prior treatment for TB (2,389 subjects):8515Reactivators who had received previous treatment:9 (0.6) 15 (0.9)11 (0.7)Reactivators who had received previous adequatec treatment5135d | NR | NR | Total deaths: 357Rate:4/1,0006.5/1,0004.4/1,000p=0.0001 for INH 1 year vs. placebo; NR for other comparisons   | 2 (0.03) deaths from TB (both received INH; 1 occurred at the 6th month of INH therapy and 1 in a patient who completed only 2 months of INH and died 11 months later) |
| Ferebee, 19634427,924 patients (566 psychiatric wards randomized); 25,210 patients included in morbidity analyses | INH 4-7 mg/kg/day (average of 5 mg/kg) x 12 months (14,407 in randomized sample; 12,884 analyzed).Placebo x 12 months (13,517; 12,326). | Cases diagnosed during first 15 months of the trial:Total4 (0.03)21 (0.17)Among those with abnormal CXR3 (0.25)14 (1.31)Among those who were tuberculin positive0 (0.0)7 (0.11)Tuberculin negative0 (0.0)0 (0.0)Unknown tuberculin status1 (0.11)0 (0.0)Cases developing after medication yearTotal15 (0.12)30 (0.24)Among those with abnormal CXR5 (0.41)9 (0.84)Among those who were tuberculin positive5 (0.08)17 (0.26)Cases appearing by May 1962 in subjects age ≥20 years in placebo groupMales <150 lbs: 21 (1.14)Males ≥150 lbs: 3 (0.20)Females <130 lbs: 8 (0.46)Females ≥130 lbs: 2 (0.10)Cases based on TB infection status in placebo group:Initial tuberculin reactions <5 mm: 4 (0.10)Initial tuberculin ≥5 mm: 24 (0.37)Abnormal roentgenogram: 23 (2.15) | NR | NR | During treatment year, among the full randomized samplee:752 (5.2)611 (4.5)Among patients who took only 1 medication (excluding crossovers):695 (5.4%)547 (4.4%) | NR |
| Veening, 196842261 | INH 600 mg (8-10 mg/kg) x 4 months, then 400 mg (5-7 mg/kg) until 1 year (133).Placebo (128). | 1 year:1 (0.8)9 (7.0)4 years:1 (0.8)12 (9.4)7 years:1 (0.8)12 (9.4) | NR | NR | NR | NR |

a No cases first 3 months after starting treatment; 1 case between months 6 and 11; 7 cases 11 months or more after starting treatment. Days index case in home by new cases: 1-60 days: 2; 61-180 days: 4; 181-270 days: 1; 270-300 days: 1.

b No cases first 3 months after starting treatment; 2 cases between months 6 and 11; 9 cases 11 months or more after starting treatment. Days index case in home by new cases: 1-60 days: 2; 61-180 days: 2; 181-270 days: 5; 270-300 days: 2.

c Adequate treatment was defined as at least 18 months of therapy with two drugs.

d Rate of reactivation was 7.3/1,000 for those with adequate prior chemotherapy and 12.7/1,000 for those with inadequate or no prior chemotherapy.

e Deaths in wards participating in the trial during the year prior to the trial: INH 801 (5.6), placebo 698 (5.2). Change in percent of deaths from year prior to the trial to the medication year: INH -0.4%; placebo -0.7%.

**Abbreviations:** CXR=chest x-ray; INH=isoniazid; N=sample size; NR=not reported; TB=tuberculosis.